Hospitals Now Control Nearly One-Third of Accredited Specialty Pharmacies
Drug Channels Institute’s 2026 mapping update quantifies a decisive power shift in U.S. pharmacy channels: hospitals and health systems now operate nearly one-third of all specialty pharmacy locations accredited by ACHC or URAC. That matters because accreditation is the ticket to payer network access and to manufacturer limited-distribution drugs. When one of every three accredited outlets sits inside a health system, vertically integrated hospital operators become structural counterweights to PBM-owned specialty pharmacies.
The momentum is driven by both policy and profit. DCI attributes the hospital expansion to manufacturers tightening 340B contract pharmacy participation, which pushes hospitals to internalize dispensing to preserve margin capture. Each in‑house fill allows retention of the 340B spread and service fees that once flowed to retail or PBM-owned channels. For payers and PBMs, this diffusion of dispensing power weakens network exclusivity and complicates rebate deals built on centralized fulfillment. Frankly, those models don’t adapt well to fragmentation.
$3.5 Billion and Full Ownership: Payers Double Down on Health‑System Services
Two major transactions define the 2025 integration wave. Evernorth Health Services, a Cigna Group subsidiary, bought 100 percent of CarepathRx and invested $3.5 billion for an undisclosed stake in Shields Health Solutions. Both firms build and manage hospital specialty pharmacy operations. These investments show payer‑PBMs shifting from direct dispensing toward infrastructure embedded within provider systems. Owning the entity that enables hospitals to run their own specialty sites keeps the payer connected to script volume even as dispensing moves in‑house.
UnitedHealth Group followed with its acquisition of CPS Solutions in 2024, another hospital‑pharmacy services company. Three separate buys across two insurance giants underscore a clear thesis: provider‑aligned pharmacy platforms are now strategic assets, not peripheral vendors. The spending patterns suggest integrated payers are trading short‑term PBM margin compression for durable influence inside the hospital channel. Smart, if you can afford the wait.
Exit Math: Centene’s Disintegration Signals Margin Pressure
Cigna and UnitedHealth are digging deeper into pharmacy adjacency, but Centene moved in the opposite direction. DCI reports that Centene outsourced its PBM operations to Express Scripts in 2024 and sold multiple subsidiaries, including Magellan Rx, PANTHERx Rare, and Magellan Specialty Health. These sales mark a retreat from the vertical integration model that dominated managed care through the early 2020s. Offloading costly specialty assets back to the market points to sub‑scale economics, limited rebate aggregation and too much capital in low‑margin fulfillment. Painfully familiar for mid‑tier players.
The contrast is telling. One set of peers spends billions to lock in hospital channel access; another prunes exposure to preserve cash. The result is a bifurcated return on integration: scale operators gain pricing leverage and network depth, while mid‑sized insurers find the capital intensity unsustainable.
Administrative Platforms Become a Hidden Integration Layer
DCI’s reclassification of affiliated third‑party administrators (TPAs) and ASO platforms into the “Insurer” category adds a new quantitative lens. Most large employers self‑fund benefits yet rely on these affiliated platforms for claims and network access. They don’t hold underwriting risk, but DCI calls them the “primary gateway to employer‑sponsored lives.” That framing matters. It implies control of claims flow, and by extension, pharmacy volume, without the balance‑sheet drag of insurance reserves. Economically, these platforms let integrated payers maintain reach in the employer market while keeping margins closer to PBM service levels. A quiet advantage that rarely makes headlines.
Inference / Speculation: The 2026‑2028 Integration Outlook
With one‑third of accredited specialty sites already hospital‑run, the next likely equilibrium, absent federal antitrust or 340B reform, lands closer to 40-50 percent provider share within two years. That shift would compress PBM specialty dispensing revenue and push integrated payers toward network service and data contracts rather than pharmacy ownership. The PBM economics model moves from dispensing margin to administrative yield. Meanwhile, mid‑tier insurers are expected to imitate Centene’s unwind to reduce capital risk. The capital rotation into hospital‑linked services like CarepathRx and Shields will continue, though probably at a slower pace as real‑world integration performance meets uneven scale realities. Investors will need to track whether Cigna’s $3.5 billion wager delivers throughput comparable to the volume diverted to hospital control. That ratio will decide whether payer‑provider alignment becomes a sustainable profit engine, or just a defensive hedge against 340B‑driven disintermediation.
